) hopes to soon introduce a pricey new pill to prevent HIV in people at risk of contracting the infection, but the drugmaker faces opposition from an unusual source: patient advocates.
Their resistance is being echoed by some insurers, including the pharmacy benefit arm of Cigna Inc, which are hinting that price will be a barrier to providing coverage for Descovy. Descovy, shown to be less toxic than Truvada to the kidneys and bones in clinical trials, was approved in 2016 for people already infected with HIV. Advisors to the U.S. Food and Drug Administration will meet on Wednesday to decide whether to recommend Descovy for PrEP, with agency approval widely expected before the end of the year.
Both Truvada and Descovy are priced at $21,000 per year, before discounts provided to public and private health insurers. In the first half of 2019, Gilead’s Truvada sales totaled $1.32 billion. Descovy sales amounted to $700 million and are expected to rise to $3 billion dollars annually by 2024, according to IBES data from Refinitiv.Teva Pharmaceutical Industries Ltd is due to sell a generic version of Truvada next year.
Hey GileadSciences might be a good time to look into buying CytoDyn $cydy
Under his eye.
Whoa, whoa, whoa. Stop the clock. There is a drug company with the same name as the brutal dictatorship in Handmaid’s Tale?
Praise be!
unfortunate name
Gilead? For real?
May the Lord Open.